Granted Patent B2

US 12,290,508 · App. 18/207,887 · Granted May 6, 2025

Inventors: Danielle Ulanet (Cambridge, MA); Sung Eun Choe (Lexington, MA)

Assignee: Servier Pharmaceuticals LLC

A61K31/4192A61P35/00

Abstract

Claims (18)

1. A method of treating double hit diffuse large B cell lymphoma or triple hit diffuse large B cell lymphoma in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof; wherein:

the dotted lines [ . . . ] in the ring represent an optional bond which may be present in any stable combination;

R 1 is selected from hydrogen and alkyl;

R 2 is -A-R 4 ;

A is arylene or tetrasubstituted arylene; wherein the substituent is halogen;

R 3 is selected from hydroxy and amino;

R 4 is selected from an aryl and a heteroaryl that is optionally substituted with one or more R 5 ;

R 5 is selected from alkyl and —(CH 2 ) n N(R a )R b ;

R a and R b are independently selected from hydrogen, alkyl and —C(O)alkyl;

alternatively R a and R b can be taken together with the nitrogen atom to which they are attached to form a 4-6 membered heterocyclyl containing 0-2 additional heteroatoms independently selected from O and N and is optionally substituted with alkyl; and

n is an integer selected from 0 and 1.

2. The method according to claim 1 , wherein the cancer is double hit diffuse large B cell lymphoma.

3. The method according to claim 1 , wherein the cancer is triple hit diffuse large B cell lymphoma.

4. The method according to claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

5. A method of treating double hit diffuse large B cell lymphoma, comprising administering to the subject a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

Assignments (3)

Continuity (2)

References Cited (130)